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Brain-derived neurotrophic factor (BDNF) is widely reported to enhance synaptic vesicle
(SV) exocytosis and neurotransmitter release. But it is still unclear whether BDNF
enhances SV recycling at excitatory terminals only, or at both excitatory and inhibitory
terminals. In the present study, in a direct comparison using cultured rat hippocampal
neurons, we demonstrate that BDNF enhances both spontaneous and activity-dependent
neurotransmitter release from excitatory terminals, but not from inhibitory terminals.
BDNF treatment for 5 min or 48 h increased both spontaneous and activity-induced
anti-synaptotagmin1 (SYT1) antibody uptake at excitatory terminals marked with vGluT1.
Conversely, BDNF treatment did not enhance spontaneous or activity-induced uptake
of anti-SYT1 antibodies in inhibitory terminals marked with vGAT. Time-lapse imaging
of FM1-43 dye destaining in excitatory and inhibitory terminals visualized by post-
hoc immunostaining of vGluT1 and vGAT also showed the same result: The rate
of spontaneous and activity-induced destaining was increased by BDNF at excitatory
synapses, but not at inhibitory synapses. These data demonstrate that BDNF enhances SV
exocytosis in excitatory but not inhibitory terminals. Moreover, BDNF enhanced evoked SV
exocytosis, even if vesicles were loaded under spontaneous vesicle recycling conditions.
Thus, BDNF enhances both spontaneous and activity-dependent neurotransmitter release
on both short and long time-scales, by the same mechanism.
Keywords: brain-derived neurotrophic factor, neurotransmitter release, exocytosis, hippocampal neurons, excita-
tory/inhibitory
INTRODUCTION
Brain-derived neurotrophic factor (BDNF) is predominantly
expressed in the CNS (Lewin and Barde, 1996) primarily by
excitatory neurons, including pyramidal neurons and granule
cells in the hippocampus (Ernfors et al., 1990; Dieni et al., 2012).
The most well-characterized effect of BDNF is its enhancement
of synaptic vesicle (SV) exocytosis (Lohof et al., 1993; Lessmann
et al., 1994; Carmignoto et al., 1997; Sherwood and Lo, 1999;
Tyler and Pozzo-Miller, 2001; Walz et al., 2006; Inagaki et al.,
2008; Amaral and Pozzo-Miller, 2012) by TrkB receptor activation
(Levine et al., 1995; Li et al., 1998; Tyler et al., 2006; Amaral
and Pozzo-Miller, 2012). Specifically, this enhancement occurs
via an increase in SV docking and release probability, which
results in an increase in quantal neurotransmitter release and
a greater number of recycling vesicles per terminal (Tyler and
Pozzo-Miller, 2001; Tyler et al., 2006). This enhancement in SV
exocytosis is thought to be associated with increased learning
and memory (Yamada and Nabeshima, 2003; Cunha et al., 2010;
Musumeci and Minichiello, 2011). Most efforts to investigate
the BDNF-induced enhancement of SV exocytosis have been
performed at excitatory terminals (Lohof et al., 1993; Lessmann
et al., 1994; Carmignoto et al., 1997; Sherwood and Lo, 1999; Tyler
and Pozzo-Miller, 2001; Walz et al., 2006; Amaral and Pozzo-
Miller, 2012), however, the enhancement of neurotransmitter
release at inhibitory terminals by BDNF has also been reported
separately (Mizuno et al., 1994; Huang et al., 1999; Baldelli et al.,
2002; Yamada et al., 2002; Ohba et al., 2005). BDNF can be
released from both pre and post-synaptic sites (Hartmann et al.,
2001; Matsuda et al., 2009) and can retrogradely enhance SV
exocytosis (Dean et al., 2009). Thus, BDNF release from excita-
tory post-synaptic neurons could retrogradely affect inhibitory
terminals.
Several mechanisms of enhanced SV exocytosis by BDNF
have been proposed. In excitatory terminals, phosphorylation of
synapsin I (Jovanovic et al., 2000), extra and intracellular Ca2+
(Amaral and Pozzo-Miller, 2012), activation of TRPC channels
(Amaral and Pozzo-Miller, 2007, 2012), and Rab3a (Thakker-
Varia et al., 2001), have all been reported to mediate BDNF-
induced enhancement of excitatory SV fusion. On the other hand,
changes in expression levels of GAD65 and vGAT have been
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proposed to mediate BDNF-induced enhancement of inhibitory
SV fusion (Mizuno et al., 1994; Yamada et al., 2002; Ohba
et al., 2005; Peng et al., 2010). Although BDNF-induced enhance-
ment of SV fusion has been reported, how quickly this effect
occurs following BDNF application, and the kinetics, degree of
enhancement and mechanisms by which it occurs in excitatory vs.
inhibitory terminals has not been directly compared. Moreover,
it is not well understood if BDNF enhances both evoked and
spontaneous SV using the same machinery.
In the present study, we carried out simultaneous analysis of
evoked and spontaneous SV recycling in excitatory and inhibitory
terminals of cultured rat hippocampal neurons and tested if SV
recycling was enhanced by BDNF treatment, using two different
optical methods. The first is static end-point visualization of SV
recycling, using uptake of anti-SYT1 antibody in live neurons
to visualize evoked and spontaneous recycling SVs by SYT1
immunostaining. The second is dynamic time-lapse imaging of
SV exocytosis by FM1-43 destaining. We discovered that: (1) both
short and long-term BDNF treatment enhanced SV fusion at
excitatory but not inhibitory terminals; (2) both evoked and
spontaneous SV fusion was enhanced in excitatory terminals,
presumably by the same mechanism; and (3) BDNF treatment
induces changes in the level of proteins associated with SV fusion,
at excitatory but not inhibitory synaptic sites.
MATERIALS AND METHODS
All research involving animals was approved by and done in accor-
dance with the Institutional Animal Care and Ethics Commit-
tees of Goettingen University (T10.31), and in accordance with
German animal welfare laws. All efforts were made to minimize
the number of animals used and their suffering.
PRIMARY HIPPOCAMPAL CELL CULTURE AND BDNF TREATMENTS
Dissociated hippocampal neurons were prepared according to
previously described methods (Banker and Goslin, 1988) with
minor modifications. Embryonic hippocampal neurons were
obtained from timed pregnant rats at 18–19 days gestation. Cells
were mechanically dissociated by trypsination and trituration.
Neurons were plated onto 0.04% polyethyleneimine (PEI, Sigma)
or 0.5 mg/ml poly-D-lysine (PDL, Sigma)-coated 12 mm glass
coverslips (with grids for retrospective immunocytochemistry for
FM1-43 experiments) in 24-well dishes at a density of 5–10× 104
cells/well. Cultures were maintained in GlutaMAX and B27-
supplemented Neurobasal medium containing 100 U/ml peni-
cillin/streptomycin (all from Invitrogen,) at 37◦C in a 5% CO2
humidified atmosphere. BDNF (R&D Systems) at a final concen-
tration of 100 ng/ml was added to culture media at 13 DIV for
48 h or at 15 DIV for 5 min.
SYT1 ANTIBODY UPTAKE
Neurons were incubated with a guinea pig polyclonal anti-SYT1
antibody (Synaptic Systems) at 1:800 in 47 mM KCl (evoked) or
4 mM KCl (basal) Tyrode solution for 5 min, and then in basal
Tyrode solution containing the same antibody concentration for
5 additional min. After washing with basal Tyrode solution for
10 min, a mouse monoclonal anti-SYT1 antibody (Synaptic Sys-
tems) was loaded in the presence of 1 µM Tetrodotoxin (TTX) in
basal Tyrode solution for 10 min for spontaneous uptake. After
washing with basal Tyrode solution for 10 min, cells were fixed
by 4% paraformaldehyde/0.1 M phosphate buffer. All incubations
except fixation were performed at 37◦C. The basal Tyrode solution
contained (in mM): 150 NaCl, 4 KCl, 2 CaCl2, 2 MgCl2, 10 Glu-
cose and 10 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES). The evoked condition high potassium Tyrode solution
contained (in mM): 107 NaCl, 47 KCl, 2 CaCl2, 2 MgCl2, 10
Glucose and 10 HEPES. The pH of the solutions was adjusted to
7.3 and osmolality to 310 mOsmol.
FM DYE IMAGING
Fluorescence microscopy was performed using a Carl Zeiss Axio
Observer Z1 inverted epifluorescence microscope equipped with
100× 1.3 NA objective and filter set for FM1-43 (472/30 nm band-
pass excitation, 511 nm longpass beamsplitter and 582/75 nm
bandpass emission). Images were acquired with a Photometrics
Evolve CCD camera controlled by MetaMorph software (Molec-
ular Devices). Coverslips of cultured neurons were transferred
to an imaging chamber that contains electrodes for electrical
stimulation (Warner Instruments). For FM1-43 unloading exper-
iments using high extracellular potassium concentrations for
depolarization, neurons were loaded with FM1-43 by incubation
with 10 µM FM1-43 (Invitrogen) in high potassium HEPES-
buffered saline (HK-HBS) containing (in mM) 107 NaCl, 47 KCl,
2 CaCl2, 2 MgCl2, 10 HEPES and 10 D-Glucose, adjusted to pH
7.3. Before unloading experiments, coverslips were placed in low
potassium HBS (LK-HBS) containing (in mM) 150 NaCl, 4 KCl, 2
CaCl2, 2 MgCl2, 10 HEPES and 10 D-Glucose, adjusted to pH 7.3.
Unloading of FM1-43 by high potassium solution was achieved
by perfusion of HK-HBS. For FM1-43 loading by field electrical
stimulation, neurons were incubated in 10 µM FM1-43 in LK-
HBS and stimulated at 20 Hz for 30 s. For FM1-43 loading by
spontaneous activity, neurons were incubated in 10 µM FM1-
43 in LK-HBS containing 1 µM TTX for 10 min. After washing
the loaded neurons for 5 min in LK-HBS, unloading of FM1-43
was achieved by field stimulation at 20 Hz for 80 s. All solutions
were supplemented with 10 µM 6-cyano-7-nitroquinoxaline-2,3-
dione (CNQX) and 50µM DL-2-amino-5-phosphonovaleric acid
(APV) to prevent recurrent excitation. All experimental proce-
dures were performed at room temperature. Images were acquired
at a rate of 1 Hz. After destaining, neurons were immediately
fixed for retrospective imunocytochemistry. To standardize imag-
ing conditions, identical solutions (blocking, antibody, FM dye,
depolarization, and wash) from a single mix in the same tube
were used for control, 5 min, and 48 h BDNF treated excitatory
and inhibitory samples. For microscopy identical magnification,
neutral density filters, lamp intensity, excitation and emission
wavelengths, camera gain, bin size, and exposure time were used
for all samples. Fluorescence intensities in the 5 min and 48 h
treated samples were normalized to control in each experiment,
and control and treated samples were imaged alternately with
identical acquisition settings in each experiment.
ROIs with synaptic characteristics; round/oval in shape, an
optical size of approximately 1 µm in diameter, and dis-
tributed along neuronal processes, were selected manually.
The bleach/spontaneous release rate was less than 0.25% per
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frame for all conditions. Background fluorescence remaining after
complete destaining (the point at which the destain curve slope
becomes zero) was subtracted to normalize complete destain
to zero. FM dye destaining curves were fit by single exponen-
tial decays after subtracting background using Excel software.
Goodness-of-fit, tested by R-squared, was greater than or equal
to 90%.
IMMUNOCYTOCHEMISTRY AND IMAGE ANALYSIS
For immunocytochemistry cultured neurons were fixed with 4%
paraformaldehyde/0.1 M phosphate buffer and then washed with
PBS. After blocking and permeabilizing in antibody buffer (2%
donkey serum, 0.1% Triton X-100, and 0.05% sodium azide in
2× PBS), cells were incubated with primary antibody in antibody
buffer at 4◦C overnight or room temp for 2 h. Cells were then
washed 3× 3 min in PBS, incubated with secondary antibody in
antibody buffer at room temp for 2 h and washed again 3× 3 min
in PBS. Coverslips were then mounted with Fluoromount Plus
(Diagnostic Biosystems) and examined using 100× objective on
a Zeiss Axiovert 200 epifluorescence microscope equipped with
a cooled CCD camera (RETIGA-SRV, Q-Imaging, Canada). To
standardize imaging conditions, identical blocking and antibody
solutions from a single mix in the same tube were used for control,
5 min, and 48 h BDNF treated excitatory and inhibitory samples.
For microscopy identical magnification, neutral density filters,
lamp intensity, excitation and emission wavelengths, camera gain,
bin size, and exposure time were used. Fluorescence intensities in
5 min and 48 h treated samples were normalized to control in each
experiment. Intensity of fluorescence of syt-1 uptake, TrkB, or
phospho-TrkB at excitatory vs. inhibitory synapses was analyzed
using MetaMorph software (Molecular Devices) by thresholding
the vGluT or vGAT signal to mark excitatory vs. inhibitory
synapses, respectively. The number of excitatory and inhibitory
synapses was counted along 40 µm secondary dendrites or 40 µm
axon, respectively. Antibodies used were: mouse and guinea pig
syt1, rabbit and guinea pig vGluT1, rabbit and mouse vGAT,
VAMP2, P/Q alpha-1A VGCC, syt3, syt9 (Synaptic Systems), SMI-
312 (Covance), synapsin1, Rab3a (kindly provided by Reinhard
Jahn, Max Planck Institute for Biophysical Chemistry, Goettin-
gen), syt12, syt17 (Abcam), MAP2 and TrkB (Millipore), and
phospho-TrkB (kindly provided by Moses Chao, New York Uni-
versity, USA). Secondary antibodies used were Alexa 488, 546 and
647 (Invitrogen) conjugated.
HIPPOCAMPAL SLICE CULTURE ANDWESTERN BLOTTING
Hippocampal slice cultures were prepared as described previously
(Fuller and Dailey, 2007) from P5 rat pups. The hippocampus
was removed from the brain and 400 µm thick slices were cut
transversely from both hippocampi in ice-cold Hank’s balanced
salt solution (HBSS) containing glucose, using a tissue chopper
(Stoelting). BDNF (100 ng/ml) was added to the slice culture
media at DIV14 for 5 min or 48 h incubation. After treatment
with 100 ng/ml BDNF for 5 min or 48 h, slices were washed
once and homogenized in 320 mM sucrose, 4 mM HEPES-KOH,
pH 7.4, in a glass-Teflon homogenizer with 10 strokes at 900
rpm. Protein concentration was determined using a BCA kit
(Calbiochem, cat. no. 71285-3) and equal protein amounts were
subjected to SDS-PAGE followed by immunoblotting. Antibodies
used for Western blotting were mouse monoclonal anti-Rab3a
and anti-tubulin, and mouse monoclonal anti-VAMP2 (all from
Synaptic Systems).
RESULTS
BDNF ENHANCES SYT1 ANTIBODY UPTAKE AT EXCITATORY, BUT NOT
INHIBITORY TERMINALS
To determine if BDNF enhances SV fusion at both excitatory and
inhibitory terminals in neurons, we used optical measurements to
directly compare SV recycling in both excitatory and inhibitory
terminals in the same experimental paradigm in response to
BDNF treatment.
We first tested the effects of BDNF using an anti-SYT1 anti-
body uptake assay and subsequent immunostaining with the
excitatory and inhibitory marker proteins vGluT1 and vGAT to
visualize SV recycling. Two different BDNF treatment times—
5 min and 48 h—were tested in both spontaneous and evoked
conditions (Figure 1A). Day in vitro (DIV) 13 hippocampal
neurons were treated with BDNF for 48 h. For short-term 5 min
BDNF treatment, 15 DIV neurons were used. At 15 DIV, a guinea
pig anti-SYT1 antibody against the lumenal domain of SYT1 was
applied in the presence of 47 mM KCl to depolarize neurons
and induce anti-SYT1 antibody uptake to visualize evoked SV
recycling. After washout of the SYT1 antibody, a mouse anti-
SYT1 lumenal domain antibody was applied in the presence of
0.1 µM TTX to suppress action potentials and allow spontaneous
anti-SYT1 antibody uptake, to visualize spontaneous SV recycling
(Figure 1A). After washout of the second SYT1 antibody, cells
were fixed and subsequently immunostained with anti-vGluT1
or anti-vGAT antibodies to observe the amount of evoked and
spontaneous SV recycling (assayed by anti-SYT1 fluorescence
intensity) in excitatory and inhibitory terminals. This method
allows a direct comparison of evoked and spontaneous uptake
of anti-SYT1 antibodies by recycling vesicles in excitatory and
inhibitory terminals (Figures 1B–G). Quantitation of anti-SYT1
fluorescence intensity revealed a significant enhancement of both
evoked and spontaneous anti-SYT1 antibody uptake in excitatory
terminals in both 5 min and 48 h BDNF treatment groups
(Figure 1C; n = 41, 26 and 33 terminals for 5 coverslips each
of control, 5 min and 48 h BDNF-treated samples, respectively,
∗ p < 0.05, ∗∗ p < 0.01, one-way ANOVA post hoc Tukey-Kramer
test). The degree of enhancement of evoked and spontaneous
uptake was identical in both 5 min and 48 h BDNF treatments
(Figure 1D). In contrast, neither evoked nor spontaneous anti-
SYT1 antibody uptake was observed in inhibitory terminals in
the same BDNF treatments (Figures 1E–G; n = 40, 24 and 33
terminals for 5 coverslips each of control, 5 min and 48 h BDNF-
treated samples, respectively).
BDNF DOES NOT CHANGE THE NUMBER OF SVs PER TERMINAL OR
SYNAPSES PER UNIT LENGTH
A possible mechanism by which BDNF could enhance SV release
is by increasing the number of SVs per terminals. To test this,
we analyzed the fluorescence intensity of vGluT1 and vGAT
immunopositive puncta in individual terminals in BDNF treated
cultures compared to control (Figures 2A,B). The fluorescence
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FIGURE 1 | Both evoked and spontaneous uptake of anti-SYT1 antibody
is enhanced by BDNF treatment in excitatory but not inhibitory
terminals. (A) Schematic of the anti-SYT1 antibody uptake experiment.
(B) Representative immunofluorescence images of evoked and spontaneous
anti-SYT1 antibody uptake in excitatory terminals. (C) Statistical analysis of
normalized fluorescence intensity of both evoked and spontaneous anti-SYT1
antibody uptake in control (white), 5 min (gray) and 48 h (black) BDNF
treatments in vGluT1 positive terminals. (D) Ratio of evoked and spontaneous
anti-SYT1 antibody uptake. (E) Representative immunofluorescence images
of evoked and spontaneous anti-SYT1 antibody uptake in inhibitory terminals.
(F) Statistical analysis of both evoked and spontaneous anti-SYT1 antibody
uptake in inhibitory terminals in control (white), 5 min (gray) and 48 h (black)
BDNF treatments. (G) Ratio of evoked and spontaneous anti-SYT1 antibody
uptake. Scale bars = 5 µm.
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FIGURE 2 | BDNF treatment does not alter total SV number or number of
excitatory or inhibitory synapses. (A) Representative immunofluorescence
images of vGluT1 immunostaining (left) and quantified data of vGluT1
fluorescence intensity in control and each BDNF treated group normalized to
control (right). Scale bar = 5 µm. (B) Representative immunofluorescence
images of vGAT immunostaining (left) and quantified data of vGAT average,
integrated and maximum fluorescence intensity in control and each BDNF
treated group normalized to control (right). Scale bar = 5 µm.
(C) Representative immunofluorescence images of excitatory (vGluT1) and
inhibitory (vGAT) synapses along dendrites (MAP2) and axons (Smi312),
respectively. Scale bar = 10 µm. (D) Quantification of number of excitatory
synapses along dendrites. (E) Quantification of number of inhibitory synapses
along axons. Statistical significance in all panels was analyzed by one-way
ANOVA.
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intensity of vGluT1 and vGAT immunopositive puncta is thought
to correlate with the number of SVs in excitatory and inhibitory
synaptic terminals, respectively. Compared with control neurons,
cultures treated for 5 min or 48 h with BDNF showed identical
fluorescence intensity of both vGluT1 (Figure 2A; n = 60, 78
and 66 terminals for 12 coverslips each of control, 5 min and
48 h BDNF-treated samples, respectively) and vGAT (Figure 2B;
n = 78, 64 and 75 terminals for 12 coverslips each of control,
5 min and 48 h BDNF-treated samples, respectively) immunopos-
itive puncta. This suggests that BDNF does not change the total
number of SVs per terminal, although we cannot exclude that SV
number is reduced while protein content per vesicle is increased,
or vice versa, resulting in no apparent change in fluorescence
intensity of the proteins tested.
BDNF has been reported to affect not only SV recycling but
also synapse number (Vicario-Abejón et al., 1998; Rico et al.,
2002; Bamji et al., 2006). No direct association between BDNF-
induced enhancement of SV fusion in excitatory terminals and
alterations in excitatory synapse number has been reported. How-
ever, a change in cellular excitability elicited by BDNF-induced
enhancement of SV fusion could indirectly affect the number
of excitatory and inhibitory synapses. To test this, we analyzed
the number of vGluT1 and vGAT immunopositive puncta along
dendrites (marked with MAP2) and axons (marked with SMI-
312). The number of excitatory vGluT1 positive terminals along
secondary dendrites identified by MAP2 staining, were identical
in control and BDNF treated neurons (Figures 2C,D; n = 18, 19
and 20 for 4 coverslips each of control, 5 min and 48 h BDNF-
treated samples, respectively, significance determined by one-way
ANOVA). Because the number of inhibitory synapses along den-
drites varies, for example between proximal and distal dendrites,
we quantified the number of vGAT positive puncta along axons
marked with SMI-312. The number of inhibitory vGAT positive
terminals along axons was also unaltered by BDNF treatment
(Figures 2C,E; n = 16, 16 and 18 for 4 coverslips each of control,
5 min and 48 h BDNF-treated samples, respectively, significance
determined by one-way ANOVA), similar to the results obtained
for excitatory terminal number. Thus, the BDNF treatments we
performed did not affect excitatory or inhibitory synapse number.
However, we cannot exclude that BDNF application promotes
dendritic/ axonal outgrowth, branching or neuronal survival,
which may result in an overall increase in synapse number.
BDNF ENHANCES FM1-43 DESTAINING FROM EXCITATORY, BUT NOT
INHIBITORY TERMINALS
The anti-SYT1 antibody uptake experiments showed that BDNF
treatment significantly enhanced SV recycling in excitatory termi-
nals but not inhibitory terminals. However, this relatively “static”
end-point experiment does not show how BDNF might alter the
kinetics of SV fusion. Moreover, antibody uptake results only
report exocytosis indirectly, based on the assumption that the
rates of exocytosis and endocytosis are coupled. We therefore
next tested SV exocytosis in real time by measuring the release
kinetics of FM1-43 from SVs by live time-lapse imaging followed
by post hoc immunostaining to identify excitatory and inhibitory
terminals. After BDNF treatment, FM1-43 was loaded by three
different protocols: 47 mM KCl, 20 Hz electrical stimulation and
spontaneous loading in the presence of 0.1 µM TTX (Figure 3A).
The former two loading protocols reflect evoked loading and the
third reflects spontaneous loading. After washout, subsequent
unloading of FM1-43 was carried out by the same protocol as
that used for loading, except in the test of spontaneous loading
followed by 20 Hz electrical stimulation unloading. All neurons
imaged by time-lapse were fixed and post hoc immunostaining was
performed with anti-vGluT1 and anti-vGAT to distinguish exci-
tatory and inhibitory terminals (Figure 3B). FM1-43 unloading
experiments showed a significant increase in FM1-43 destaining
kinetics in excitatory terminals in cultures treated with BDNF for
5 min or 48 h, consistent with the anti-SYT1 antibody uptake
results (Figure 3C: n = 8–15; 20 Hz τ = 26.1 ± 1.6 (control),
14.2 ± 1.2 (5 min), 14.1 ± 1.8 (48 h), p < 0.001 (∗∗∗) for control
vs. 5 min or 48 h BDNF; spont. τ = 28.2± 1.0 (control), 19.5± 2.7
(5 min), 17.4 ± 2.3 (48 h), p < 0.01 (∗∗) for control vs. 5 min
or 48 h BDNF, one-way ANOVA post hoc Tukey-Kramer test;
R-squared ≥ 90%). No enhancement of FM1-43 dye destaining
kinetics was observed in the 47 mM KCl load-unload experiment,
most likely because this relatively strong stimulation results in a
maximal rate of destain (47 mM KCl τ = 10.3 ± 1.4 (control),
10.3 ± 2.6 (5 min), 8.7 ± 0.9 (48 h)). However, the initial loaded
FM1-43 fluorescence intensities were significantly increased in
BDNF treated cultures compared to control (Figure 3C, upper
right inset graph). In contrast, no enhancement of FM1-43
load or destaining kinetics was observed in inhibitory terminals
following BDNF treatment in spontaneous, 47 mM KCl or 20
Hz electrical stimulation load-unload conditions (Figure 3D:
n = 8–15; 47 mM KCl τ = 8.2 ± 1.0 (control), 12.1 ± 2.0
(5 min), 9.5 ± 0.7 (48 h); 20 Hz τ = 20.4 ± 2.5 (control),
16.7 ± 2.8 (5 min), 19.1 ± 3.6 (48 h); spont. τ = 17.6 ± 2.2
(control), 17.0 ± 2.7 (5 min), 20.1 ± 3.2 (48 h); R-squared
≥ 90%).
TrkB DISTRIBUTION AND PHOSPHORYLATION FOLLOWING BDNF
ADDITION IS IDENTICAL AT EXCITATORY AND INHIBITORY SYNAPSES
The specific effect of BDNF on excitatory SV recycling could
be caused by more TrkB receptors at excitatory synapses, or
more TrkB phosphorylation at excitatory synapses. To test this
we immunostained control and BDNF-treated hippocampal cul-
tures with TrkB or phospho-TrkB antibodies and vGluT and
vGAT to mark excitatory and inhibitory synapses, respectively
(Figure 4). TrkB receptors were enriched at synaptic sites, but
were present at both excitatory and inhibitory synapses in
equal amounts (Figures 4A–C). TrkB phosphorylation increased
significantly following BDNF treatment for 48 h, but did so
in equal amounts at both excitatory and inhibitory synapses
(Figures 4D–F; n = 9 images from three different cultures for
each condition, ∗ p< 0.05, Student’s t-test). Thus the distribution
or phosphorylation of TrkB receptors themselves is not the cause
of differences in BDNF-induced SV recycling at excitatory vs.
inhibitory synapses.
BDNF TREATMENT DECREASES VAMP2 AND Rab3a LEVELS IN
EXCITATORY TERMINALS
BDNF treatment could affect SV fusion by modifying the associ-
ation of proteins with SVs or active zones on short time scales,
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FIGURE 3 | Both evoked and spontaneous destaining of FM1-43 dye is
enhanced by BDNF treatment in excitatory but not inhibitory terminals.
(A) Schematic of the FM1-43 staining and destaining experiment.
(B) Representative time-lapse image frames of FM1-43 destaining and
post hoc vGluT1 and vGAT immunostaining. Scale bar is 5 µm. (C) Time
course of FM1-43 fluorescence destaining using the indicated loading and
unloading protocols in excitatory terminals. Data were normalized to the initial
fluorescence intensity of each FM1-43 fluorescent punctum. Insets indicate
the initial value of FM1-43 fluorescence in loaded presynaptic terminals.
(D) Time course of FM1-43 fluorescence destaining using the indicated
loading and unloading protocols in inhibitory terminals. Data were normalized
to the initial fluorescence intensity of each FM1-43 fluorescent punctum.
Inset graphs indicate the initial value of FM1-43 fluorescence in loaded
presynaptic terminals.
or by changing protein expression levels over longer time periods
(Tartaglia et al., 2001; Alder et al., 2003). We therefore examined
the levels of proteins reported to be associated with BDNF-
induced SV release in excitatory and inhibitory terminals by
quantitative immunostaining. We hypothesized that the levels of
some of these proteins may be altered specifically in excitatory
terminals in response to BDNF treatment. BDNF treated cul-
tures were fixed and immunostained with antibodies against SV
related proteins together with anti-vGluT1 and vGAT to identify
excitatory and inhibitory terminals. The fluorescence intensity of
each antibody was quantified in excitatory and inhibitory termi-
nals. For most antibodies tested, there was no change in levels
at excitatory or inhibitory synapses following BDNF treatment.
However, the fluorescence intensity of Rab3a and VAMP2 in
excitatory terminals was slightly (but not significantly) decreased
following 5 min BDNF treatment, and significantly decreased
following 48 h BDNF treatment (Figures 5A,B; n = 12 each for
all proteins in control, 5 min and 48 h BDNF-treated samples,
∗ p < 0.05, ∗∗ p < 0.01, one-way ANOVA post hoc Tukey-Kramer
test). In addition, we tested if the total protein levels of Rab3a
or VAMP2 were decreased in hippocampal slices in response
to BDNF treatment. We found a significant decrease in Rab3a
following 48-h treatment with BDNF (Figure 6; ∗ p < 0.05,
Student’s t-test).
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FIGURE 4 | Levels of TrkB and phosphorylated TrkB are the same at
excitatory and inhibitory synapses. (A) Hippocampal neurons in control
conditions and treated with BDNF for 5 min or 48 h and immunostained for
TrkB, vGluT and vGAT. (B) Quantitation of arbitrary fluorescent units and
normalized (C) TrkB intensity at excitatory (vGluT-positive) or inhibitory
(vGAT-positive) synapses in control and BDNF-treated conditions.
(D) Control and BDNF-treated hippocampal neurons immunostained for
phospho-TrkB, vGluT and vGAT. (E) Quantitation of arbitrary fluorescent
units and normalized (F) phospho-TrkB intensity at excitatory
(vGluT-positive) or inhibitory (vGAT-positive) synapses. Scale bars = 10 µm.
DISCUSSION
Our main finding in the present study is that BDNF enhances SV
recycling at excitatory synapses but not at inhibitory synapses. In
addition, our findings lead to three conclusions: (1) both short
and long-term BDNF treatment enhance SV fusion and recycling
at excitatory but not inhibitory terminals; (2) BDNF enhances
both evoked and spontaneous SV release, suggesting a similar
mechanism in each case; and (3) long-term BDNF treatment
changes the levels of proteins associated with BDNF-induced SV
release at excitatory but not inhibitory terminals.
In excitatory terminals, distinct SV pools that undergo evoked
vs. spontaneous fusion have been reported (Sara et al., 2005;
Fredj and Burrone, 2009), although this is debated (Groemer and
Klingauf, 2007). We found that BDNF has similar effects on both
spontaneous and evoked excitatory SV recycling. In addition,
BDNF enhanced evoked release even when vesicles were loaded
with FM dye under spontaneous recycling conditions, suggesting
that it operates by a similar mechanism to enhance these two
types of fusion events. Vesicle pools are more heterogeneous at
glutamatergic than GABAergic synapses (Moulder et al., 2007),
suggesting that excitatory SVs are more malleable and capable of
being modified by BDNF.
What is the mechanism by which BDNF enhances neuro-
transmitter release at excitatory synapses and not at inhibitory
synapses? TrkB is present at both synapse types (Figure 4;
Swanwick et al., 2004) making it unlikely that TrkB itself plays
a role. We found significantly altered levels of the SV associated
proteins Rab3a and VAMP2 at excitatory synapses and not at
inhibitory synapses in response to BDNF treatment, suggesting
that these proteins play a role in modifying SV recycling in
response to BDNF. Both Rab3a and VAMP2 were significantly
decreased at excitatory synapses by BDNF treatment. Rab3a dis-
sociates from SV during exocytosis (Fischer von Mollard et al.,
1991) and thus might be expected to be reduced at presynaptic
terminals that are highly active. Our results are consistent with
early reports that more exocytosis occurs in Rab3a knockouts
compared to wild-type synapses (Geppert et al., 1997). A BDNF-
induced decrease in Rab3a specifically at excitatory synapses
would then be expected to increase exocytosis at these synapses,
and this is indeed what we observe. VAMP2 also disperses in the
plasma membrane following fusion (Degtyar et al., 2013), which
may result in an apparent decrease in fluorescence at more active
synapses. But both Rab3a and VAMP2 proteins are present at
both excitatory and inhibitory synapses, and are thus unlikely to
initiate the BDNF-induced effect. A proteomics comparison of
excitatory and inhibitory SV associated proteins yielded relatively
few proteins that were specifically localized to one vesicle sub-
type (Grønborg et al., 2010), suggesting that vesicle proteins
themselves may not cause the BDNF-induced effect. It may,
nonetheless, be interesting to immunoprecipitate vGluT1 and
vGAT-containing vesicles from cultures treated with BDNF to test
if SV composition changes in one vesicle type and not the other.
A more likely but as yet unexplored possibility for the mecha-
nism by which BDNF affects excitatory SV recycling is via a post-
synaptic protein present at excitatory synapses and not inhibitory
synapses. Neuroligin1, for example, is specifically localized to
excitatory post-synaptic sites, and can retrogradely enhance the
size of the recycling SV pool at apposed presynaptic terminals
(Wittenmayer et al., 2009). BDNF may bind to post-synaptic
TrkB receptors and signal via neuroligin1 to presynaptic sites to
enhance SV recycling. Alternatively, it is possible that different
times and concentrations of BDNF could affect excitatory vs.
inhibitory SV recycling differently, and the time and concentra-
tion we chose predominantly affects excitatory synapses. This
seems unlikely, however, since we specifically chose times and
concentrations of BDNF that are commonly reported to enhance
both excitatory and inhibitory synapses.
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FIGURE 5 | VAMP2 and Rab3a are decreased by long-term
BDNF treatment in excitatory but not inhibitory terminals.
(A) Representative immunofluorescence images of Rab3a and
VAMP2 in excitatory and inhibitory terminals in control conditions
and following treatment with BDNF for 5 min or 48 h.
(B) Quantified immunofluorescence of synaptic proteins in
excitatory or inhibitory terminals in 5 min and 48 h BDNF
treated groups compared to control. Scale bars = 5 µm.
Our results are similar to those reporting BDNF-induced
enhancement of excitatory SV recycling (Lohof et al., 1993;
Lessmann et al., 1994; Carmignoto et al., 1997; Sherwood and
Lo, 1999; Tyler and Pozzo-Miller, 2001; Walz et al., 2006;
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FIGURE 6 | Rab3a protein levels are decreased in response to 48 h
BDNF treatment. (A) Western blot of Rab3a and VAMP2 in
hippocampal slices treated with BDNF for 5 min or 48 h compared to
control. (B) Quantitation of Rab3a and VAMP2 levels in Western blots
of homogenate from hippocampal slices from three different samples,
normalized to tubulin levels.
Amaral and Pozzo-Miller, 2012), but differ from reports of
enhanced inhibitory SV recycling (Mizuno et al., 1994; Huang
et al., 1999; Baldelli et al., 2002; Yamada et al., 2002; Ohba
et al., 2005). However, many reports of inhibitory effects of
BDNF implicate SV recycling indirectly. For example, an observed
increase in GABA content in the striatum after BDNF injections
(Mizuno et al., 1994) could be caused by increased GABAer-
gic release, or by increased synthesis. Similarly, BDNF-induced
increases in miniature or evoked GABAergic release (Baldelli
et al., 2002; Yamada et al., 2002) could be caused by an increase
in GABAergic release probability or an increase in GABAergic
synapse number. This raises the possibility that the inhibitory
effects of BDNF are caused by alternative mechanisms, some of
which may be post-synaptic (Brünig et al., 2001; Wardle and Poo,
2003). Tanaka et al. (1997), for example, reported suppression
of inhibition by BDNF entirely by a postsynaptic mechanism. It
is also likely, given the bulk of the literature, that BDNF affects
excitatory SV recycling at mature synapses, but affects GABAergic
transmission specifically during development and synapse matu-
ration (Huang et al., 1999; Baldelli et al., 2002; Rico et al., 2002;
Yamada et al., 2002). In any case, there is no question that BDNF
affects both excitatory and inhibitory synapse function.
It is important to note that dissociated hippocampal cul-
tures likely do not represent native in vivo hippocampal cir-
cuits. The effects of BDNF could depend on the activity and
connectivity state of the neurons in a circuit. For example,
BDNF enhances evoked excitatory SV recycling when both pre
and post-synaptic cells are excitatory, but not at excitatory-
inhibitory synapses (Schinder et al., 2000). In addition, in
organotypic hippocampal cultures, BDNF increases synapse
numbers (Tyler and Pozzo-Miller, 2001; Amaral and Pozzo-
Miller, 2007), but in studies in dissociated culture, including
ours, BDNF does not change synapse numbers (Sherwood and
Lo, 1999; Bolton et al., 2000). The reduced dissociated culture
system we used, however, is an advantage because it allows
us to assess intrinsic cellular effects of BDNF at individual
synapses using imaging approaches. In addition, although exoge-
nous BDNF is widely used to study its function, it does not
reflect the native source of BDNF. Endogenous BDNF is likely
released from specific sites in specific amounts at specific times
to affect synapse function. In this study we used exogenous
BDNF to isolate the effects of BDNF irrespective of its site of
release.
The diverse and intricate roles of BDNF reported in a variety
of cellular and synaptic processes, using different experimental
techniques, makes it difficult to discern specific effects. Our
goal in the present study was to directly test one of the most
commonly reported effects of BDNF, i.e., the enhancement of
SV recycling, where it is unclear if this occurs at excitatory
synapses, inhibitory synapses, or both. We used two different
assays to directly examine effects of both short and long-term
BDNF treatment on SV recycling, bypassing potential post-
synaptic effects and changes in synapse number that cannot be
excluded in electrophysiological experiments. Our combination
of anti-SYT1 antibody uptake and FM dye destaining experi-
ments, which reflect the size of the SV recycling pool and release
probability at synapses (Branco et al., 2008; Tokuoka and Goda,
2008) showed that BDNF specifically affects SV recycling at
excitatory synapses and not at inhibitory synapses. This direct
comparison more clearly defines the specific role of BDNF in
a distinct pathway—SV recycling—that affects synapse strength
and underlies BDNF-induced changes in circuit function and
plasticity.
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